Patent intelligence · US
US 11866491
Antibody for binding to interleukin 4 receptor
Antibody for binding to interleukin 4 receptor
Patent details — US 11866491
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 9, 2024
- Expiration
- Jan 4, 2044
- Applicant
- SuZhou Connect Biopharmaceuticals, Inc.
- Claims
- 32
- CPC classes
- A61K, A61K38/00, A61K39/395, A61K45/06
Quick answer
US 11866491 (Antibody for binding to interleukin 4 receptor) is held by SuZhou Connect Biopharmaceuticals, Inc.. Status: granted. Granted Jan 9, 2024. Expires Jan 4, 2044 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SuZhou Connect Biopharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 32
- CPC classes
- A61K, A61K38/00, A61K39/395, A61K45/06, A61P, A61P29/00
More from SuZhou Connect Biopharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12311017
Identification of immunologically protective neo-epitopes for the treatment of cancers
granted -
US 12251378
Long-acting local anesthetic formulation
granted -
US 12202822
Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition
granted -
US 12156879
Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy
granted -
US 12060555
MicroRNA-33 inhibitors and use thereof in the treatment of pulmonary fibrosis
granted -
US 12029787
Method for generating recombinant poxviruses
granted -
US 12018255
Compositions and methods for treating disorders of genomic imprinting
granted -
US 11952419
Reagents and methods for treating cancer and autoimmune disease
granted
Frequently asked questions
What is US patent 11866491?
US 11866491 (Antibody for binding to interleukin 4 receptor) is held by SuZhou Connect Biopharmaceuticals, Inc.. Status: granted. Granted Jan 9, 2024. Expires Jan 4, 2044 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11866491?
SuZhou Connect Biopharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 179 pharmaceutical patents for this assignee.
When does US 11866491 expire?
Our index shows an expiration date of Jan 4, 2044 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.